Hardcore Insights and Practical Guidance on Biotech Overseas Financing: Secure Your Spot at the 2025 China Biotech Overseas Financing Training – Shenzhen Guangming Bay Gravity Station!

May 20, 2025 15:15 CST Updated 15:15

最新主K.jpg

In recent years, the internationalization of China’s biopharmaceutical industry has shown a significant acceleration. Between 2021 and 2023, the wave of overseas pharmaceutical companies establishing their presence in China continued to intensify alongside the boom in global asset transactions. Although the global scale of biopharmaceutical transactions declined year-on-year in 2024, the transaction value of Chinese assets bucked the trend, currently accounting for approximately 30% of the global total. This trend is reflected not only in the sustained leadership in traditional areas of strength such as antibody-drug conjugates (ADCs), but also in the gradual expansion into bispecific antibodies (TCEs) and VEGF/PD(L)1DoubleThe expansion into hot sectors such as novel targets and GLP-1 receptor agonists demonstrates the competitiveness of Chinese innovative pharmaceutical companies across multiple fields.

However, the competitive model that relies solely on the speed of target development and the efficiency of clinical translation is gradually becoming ineffective. Industry consensus indicates that the projects capable of truly building competitive barriers in the future will be those with “First-in-class” breakthrough capabilities or “Best-in-class” advantages.and overseas market operational capabilitiesIn this context, innovation-driven global expansion models represented by NewCo formations and license-out deals have become critical pathways for domestic pharmaceutical companies to overcome financing challenges and expand into international markets. Public data shows that in 2023, both the number and value of license-out transactions involving Chinese innovative drug companies reached record highs, marking the transition of “global expansion” from strategic pilots by a few pioneers to a collective industry-wide movement.

Despite the promising prospects, Chinese pharmaceutical companies still face multiple challenges on their path to globalization. On one hand, issues such as insufficient systematic understanding of the entire overseas financing process, frequent legal and intellectual property disputes, and a disconnect between pipeline design and international clinical standards are commonplace; on the other hand, the dual pressures of a domestic capital winter and tightening overseas policies have made it difficult for many biotech companies to cross the financing threshold, even with high-quality pipelines in hand. These pain points not onlyThis not only tests a company’s technical capabilities but also imposes higher demands on its strategic planning, regulatory compliance, and resource integration.

To supportChinese biotech companiesBreaking Through the Financing Bottleneck for Overseas Expansion, VCBeat and Niukou Capital Jointly Planned “2025 Practical Guide to Overseas Fundraising for Chinese Biotech Companies”Series of Training Activities. The Event Brings TogetherNewCo model operators, partners of top-tier US dollar funds, multinational legal experts, executives from successfully funded enterprises, and heads of Business Development at multinational corporations (MNCs), aroundPractical Guide to the Full Process of Overseas Financing、Legal and Intellectual Property Risk Mitigation、International Tax Planning、MNC Project Selection Criteria、Global Clinical Development Strategy...and other core topics. Through case study analysis and practical simulations, the event aims to provide Chinese pharmaceutical companies with systematic solutions ranging from strategy to implementation, helping them gain a competitive edge in global markets.

To date, the first and second sessions of the training program have been successfully held in Beijing and Suzhou. The third session is scheduled to take place on May 29–30 in Shenzhen at Guangming Bay You Yin Li (Guangming Biopharmaceutical Innovation Center). We cordially invite those who are planning or currently advancing overseas fundraising effortsChinaFounders, CEOs, CFOs, Heads of Financing, and Senior Executives in Strategy Departments at Biotech Companies；FollowInvestors and Legal Advisors for Overseas Financing in the Biotech SectorParticipate!

Phase I On-Site

Phase II On-Site

Training Content

From0-1 Systematic Explanation：In-Depth Analysis of the NewCo Model

Button Capital and Enterprises Practicing the NewCo Model Will Conduct an In-Depth Analysis of the “Past and Present” of the NewCo Model, and share practical implementation strategies through real-world case studies.

From the Perspective of the Demand Side: WithFace-to-Face with MNCs and USD Funds

This training will analyze the strategic layouts and collaboration needs of multinational corporations (MNCs) and interpret the investment preferences and decision-making processes of US dollar funds from the perspective of capital seekers. Enterprises will have the opportunity to engage directly with potential partners, understand their expectations and concerns, and thereby increase their success rate in securing financing.

Key Stages of the Process: Legal Firms and Tax Experts Provide Safeguards

Leading law firms and tax experts will be on-site to provide guidance, covering key areas such as legal compliance, contract terms, international tax regulations, intellectual property protection, and cross-border transaction risk mitigation. Their expertise will help businesses establish a robust legal framework, ensuring a smooth and uninterrupted financing process.

CommunicationDinner Gala: Engage closely with industry leaders, speak freely, and get your questions answered

The training program specially features an industry networking dinner with structured open-discussion sessions, offering participants the opportunity to engage in-depth with industry leaders, peer elites, and potential partners, thereby broadening their horizons and establishing more extensive collaborative relationships.

Training Agenda